原发性乳腺癌低剂量环磷酰胺诱导的低钠血症

Clinical case reports and reviews Pub Date : 2020-01-01 DOI:10.15761/CCRR.1000491

Y. Tono, T. Mizuno, H. Oda, M. Ishihara, Kanako Saito, Y. Yamashita, K. Nakase

{"title":"原发性乳腺癌低剂量环磷酰胺诱导的低钠血症","authors":"Y. Tono, T. Mizuno, H. Oda, M. Ishihara, Kanako Saito, Y. Yamashita, K. Nakase","doi":"10.15761/CCRR.1000491","DOIUrl":null,"url":null,"abstract":"Hyponatremia is the most common electrolyte disturbance seen in patients receiving anticancer drugs. Several cytotoxic agents, including carboplatin, cisplatin, vincristine, and vinblastine, have been found to cause hyponatremia. Recently, clinically significant hyponatremia has been reported in cancer patients treated with moleculartargeted therapies [1]. Moreover, several studies have suggested that hyponatremia is a poor prognostic factor among cancer patients [2,3].","PeriodicalId":72607,"journal":{"name":"Clinical case reports and reviews","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Low-dose cyclophosphamide-induced hyponatremia in primary breast cancer\",\"authors\":\"Y. Tono, T. Mizuno, H. Oda, M. Ishihara, Kanako Saito, Y. Yamashita, K. Nakase\",\"doi\":\"10.15761/CCRR.1000491\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hyponatremia is the most common electrolyte disturbance seen in patients receiving anticancer drugs. Several cytotoxic agents, including carboplatin, cisplatin, vincristine, and vinblastine, have been found to cause hyponatremia. Recently, clinically significant hyponatremia has been reported in cancer patients treated with moleculartargeted therapies [1]. Moreover, several studies have suggested that hyponatremia is a poor prognostic factor among cancer patients [2,3].\",\"PeriodicalId\":72607,\"journal\":{\"name\":\"Clinical case reports and reviews\",\"volume\":\"6 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical case reports and reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15761/CCRR.1000491\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical case reports and reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/CCRR.1000491","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

摘要

低钠血症是接受抗癌药物的患者中最常见的电解质紊乱。一些细胞毒性药物，包括卡铂、顺铂、长春新碱和长春碱，已被发现可引起低钠血症。最近，有报道称在接受分子靶向治疗的癌症患者中出现了临床显著的低钠血症。此外，一些研究表明，低钠血症是癌症患者预后不良的因素[2,3]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Low-dose cyclophosphamide-induced hyponatremia in primary breast cancer

Hyponatremia is the most common electrolyte disturbance seen in patients receiving anticancer drugs. Several cytotoxic agents, including carboplatin, cisplatin, vincristine, and vinblastine, have been found to cause hyponatremia. Recently, clinically significant hyponatremia has been reported in cancer patients treated with moleculartargeted therapies [1]. Moreover, several studies have suggested that hyponatremia is a poor prognostic factor among cancer patients [2,3].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical case reports and reviews

自引率

0.00%

发文量